Biopharma Co. Escapes Investor Suit Over Drug Approval Lies

By Sydney Price · October 29, 2024, 6:36 PM EDT

Biopharmaceutical company Spero Therapeutics Inc. has escaped a proposed investor class action accusing it of concealing warning signs that it would not secure regulatory approval of one of its drugs, with...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

In Re Spero Therapeutics, Inc. Securities Litigation

Case Number

1:22-cv-03125

Court

New York Eastern

Nature of Suit

Securities/Commodities

Date Filed

May 26, 2022